PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate within one year of study entry. Evaluation can happen outside of MD Anderson as long as histological confirmation takes place at MD Anderson.
• cT1c-T3a by digital exam or imaging (AJCC 8th Ed.). No cT3b-4 by digital exam or imaging (AJCC 8th Ed.)
• Gleason Grade Group 2-5 (Gleason 7, 8, 9, 10).
• If Gleason Grade 2, must meet definition of unfavorable intermediate risk (at least one of the following: cT2b, and/or ≥ 50% biopsy cores positive, and/or PSA >10 ng/mL prior to starting androgen deprivation therapy (ADT).
• If a participant is taking 5-alpha reductase inhibitors the measured PSA may be doubled).
• Node negative by conventional imaging.
• Be ≥ 18 years of age on the day of signing informed consent.
• Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is ≤ 185 days prior to registration; Please note: baseline PSA must be obtained prior to the start of any ADT.
• ECOG performance status 0-2.

You cannot join if

• Diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe RT.
• Prior prostatectomy, cryosurgery, or HIFU for adenocarcinoma of the prostate
• Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields
• Distant metastatic disease on conventional imaging, which by the discretion of the treating physician cannot be treated definitively.

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

Treatments listed in the registry

• Stereotactic Body Radiation Therapy (Device): Undergo Radiation Therapy

Na · Single Group · masking: None

As the registry describes them. Requirements to join, such as a tissue sample, are in the eligibility list above even when on-study procedures are optional. Ask the study team which steps apply to you.

• questionnaires: Part of the study plan
• radiation: Part of the study plan

Main goals

• Safety and adverse events (AEs) (Through study completion; an average of 1 year)

Planned enrollment: 100 (estimated).

• MD Anderson Cancer Center, Houston, Texas

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT06369246

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Aug 20, 2026. Public record; not medical advice.